Literature DB >> 16735500

Global gene expression analysis of ERK5 and ERK1/2 signaling reveals a role for HIF-1 in ERK5-mediated responses.

Rebecca E Schweppe1, Tom Hiu Cheung, Natalie G Ahn.   

Abstract

ERK5 is a recently characterized MAPK, which is most similar to the well studied ERK1/2 subfamily but uses distinct mechanisms to elicit responses. To understand the specificity of signaling through ERK5 versus ERK1/2, we examined global gene expression changes in response to each pathway. Microarray measurements in retinal pigment epithelial cells revealed 36 genes regulated by ERK5, all which were novel targets for this pathway. 39 genes were regulated by ERK1/2, which included 11 known genes. Of these genes, 19 were regulated by both pathways. Inspection of the 17 genes uniquely regulated by ERK5 revealed that 14 genes (82%) were previously associated with hypoxia via regulation by HIF-1. In contrast, 16 genes (84%) regulated by either ERK5 or ERK1/2 were implicated in hypoxia, most through mechanisms independent of HIF-1. Of the 20 genes regulated by ERK1/2, only 9 were implicated in hypoxia and were not well characterized hypoxia targets. Thus, unlike ERK5, a mechanistic link between ERK1/2 and HIF-1/HRE could not be established on the basis of gene regulation. Activation of both pathways enhanced transcription from a hypoxia-response element and increased HIF-1alpha protein expression. In contrast, ERK5 but not ERK1/2 elevated transcription through GAL4-HIF-1. Most interestingly, ERK5 is not significantly activated by hypoxia in retinal pigment epithelial cells, indicating that ERK5 regulation of these genes is relevant in normoxia rather than hypoxia. Thus, ERK5 and ERK1/2 differ in their mechanisms of gene regulation, and indicate that ERK5 may control hypoxia-responsive genes by a mechanism independent of HIF-1alpha expression control.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16735500     DOI: 10.1074/jbc.M604208200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

1.  Effects of MAPK signaling on 1,25-dihydroxyvitamin D-mediated CYP24 gene expression in the enterocyte-like cell line, Caco-2.

Authors:  Min Cui; Yan Zhao; Kenneth W Hance; Andrew Shao; Richard J Wood; James C Fleet
Journal:  J Cell Physiol       Date:  2009-04       Impact factor: 6.384

2.  A novel role of ERK5 in integrin-mediated cell adhesion and motility in cancer cells via Fak signaling.

Authors:  Rajinder S Sawhney; Wensheng Liu; Michael G Brattain
Journal:  J Cell Physiol       Date:  2009-04       Impact factor: 6.384

3.  Role of the phosphatidylinositol-3-kinase and extracellular regulated kinase pathways in the induction of hypoxia-inducible factor (HIF)-1 activity and the HIF-1 target vascular endothelial growth factor in ovarian granulosa cells in response to follicle-stimulating hormone.

Authors:  Hena Alam; Jennifer Weck; Evelyn Maizels; Youngkyu Park; Eun Jig Lee; Margaret Ashcroft; Mary Hunzicker-Dunn
Journal:  Endocrinology       Date:  2008-10-09       Impact factor: 4.736

4.  Activation of the oxidative stress pathway by HIV-1 Vpr leads to induction of hypoxia-inducible factor 1alpha expression.

Authors:  Satish L Deshmane; Ruma Mukerjee; Shongshan Fan; Luis Del Valle; Carine Michiels; Thersa Sweet; Inna Rom; Kamel Khalili; Jay Rappaport; Shohreh Amini; Bassel E Sawaya
Journal:  J Biol Chem       Date:  2009-02-09       Impact factor: 5.157

5.  MAP kinase kinase kinase-2 (MEKK2) regulates hypertrophic remodeling of the right ventricle in hypoxia-induced pulmonary hypertension.

Authors:  R Dale Brown; S Kelly Ambler; Min Li; Timothy M Sullivan; Lauren N Henry; Joseph T Crossno; Carlin S Long; Timothy P Garrington; Kurt R Stenmark
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-11-02       Impact factor: 4.733

6.  Breast tumor kinase (Brk/PTK6) is a mediator of hypoxia-associated breast cancer progression.

Authors:  Tarah M Regan Anderson; Danielle L Peacock; Andrea R Daniel; Gregory K Hubbard; Kristopher A Lofgren; Brian J Girard; Alexandra Schörg; David Hoogewijs; Roland H Wenger; Tiffany N Seagroves; Carol A Lange
Journal:  Cancer Res       Date:  2013-08-08       Impact factor: 12.701

7.  ERK5/BMK1 is a novel target of the tumor suppressor VHL: implication in clear cell renal carcinoma.

Authors:  Laura Arias-González; Inmaculada Moreno-Gimeno; Antonio Rubio del Campo; Leticia Serrano-Oviedo; María Llanos Valero; Azucena Esparís-Ogando; Miguel Ángel de la Cruz-Morcillo; Pedro Melgar-Rojas; Jesús García-Cano; Francisco José Cimas; María José Ruiz Hidalgo; Alfonso Prado; Juan Luis Callejas-Valera; Syong Hyun Nam-Cha; José Miguel Giménez-Bachs; Antonio S Salinas-Sánchez; Atanasio Pandiella; Luis del Peso; Ricardo Sánchez-Prieto
Journal:  Neoplasia       Date:  2013-06       Impact factor: 5.715

8.  The class II transactivator (CIITA) is regulated by post-translational modification cross-talk between ERK1/2 phosphorylation, mono-ubiquitination and Lys63 ubiquitination.

Authors:  Julie E Morgan; Ronald L Shanderson; Nathaniel H Boyd; Ercan Cacan; Susanna F Greer
Journal:  Biosci Rep       Date:  2015-06-19       Impact factor: 3.840

9.  An integrative computational systems biology approach identifies differentially regulated dynamic transcriptome signatures which drive the initiation of human T helper cell differentiation.

Authors:  Tarmo Aijö; Sanna M Edelman; Tapio Lönnberg; Antti Larjo; Henna Kallionpää; Soile Tuomela; Emilia Engström; Riitta Lahesmaa; Harri Lähdesmäki
Journal:  BMC Genomics       Date:  2012-10-30       Impact factor: 3.969

10.  Tongxinluo Improves Cardiac Function and Ameliorates Ventricular Remodeling in Mice Model of Myocardial Infarction through Enhancing Angiogenesis.

Authors:  Wen-Wu Bai; Yi-Fan Xing; Bo Wang; Xiao-Ting Lu; Ying-Bin Wang; Yuan-Yuan Sun; Xiao-Qiong Liu; Tao Guo; Yu-Xia Zhao
Journal:  Evid Based Complement Alternat Med       Date:  2013-08-27       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.